Platelet serotonin transporter and 5-HT_2A receptor binding in adolescents with eating disorders

References

• Bailer UF, Kaye WH. Serotonin: imaging findings in eating disorders. Curr Top Behav Neurosci 2011;6:59–79.
   Google Scholar
• Kaye WH, Frank GK, Bailer UF, et al. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiol Behav 2005;85:73–81.
   PubMed Web of Science ®Google Scholar
• Brewerton TD. Towards a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinol 1995;20:561–90.
   PubMed Web of Science ®Google Scholar
• Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319–22.
   PubMed Web of Science ®Google Scholar
• Andres AH, Rao ML, Ostrowitski S, Entzian W. Human brain cortex and platelet serotonin-2 receptor binding properties and the regulation by endogenous serotonin. Life Sci 1993;52:313–21.
   PubMedGoogle Scholar
• Elliott JM, Kent A. Comparison of [125I]iodlysergic acid diethylamide binding in human frontal cortex and platelet tissue. J Neurochem 1989;53:191–6.
   PubMedGoogle Scholar
• Ramacciotti CE, Coli E, Paoli R, et al. Serotonergic activity measured by platelet [3H]paroxetine binding in patients with eating disorders. Psychiatry Res 2003;118:33–8.
   PubMedGoogle Scholar
• Steiger H, Gauvin L, Israël M, et al. Serotonin function, personality-trait variations, and childhood abuse in women with bulimia-spectrum eating disorders. J Clin Psychiatry 2004;65:830–7.
   PubMedGoogle Scholar
• Steiger H, Richardson J, Israel M, et al. Reduced density of platelet-binding sites for [3H]paroxetine in remitted bulimic women. Neuropsychopharmacol 2005;30:1028–32.
   PubMedGoogle Scholar
• Bruce KR, Steiger H, Ng Ying Kin NM Reduced platelet [3H]paroxetine binding in anorexia nervosa: relationship to eating symptoms and personality pathology. Psychiatry Res 2006;142:225–32.
   PubMedGoogle Scholar
• Ekman A, Sundblad-Elverfors C, Landén M, et al. Low density and high affinity of platelet [3H]paroxetine binding in women with bulimia nervosa. Psychiatry Res 2006;142:219–23.
   PubMedGoogle Scholar
• Spigset O, Andersen T, Hägg S, Mjörndal T. Enhanced platelet serotonin 5-HT2A receptor binding in anorexia nervosa and bulimia nervosa. Eur Neuropsychopharmacol 1999;9: 469–73.
   PubMedGoogle Scholar
• Lowry DH, Rosenbrough HJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265–75.
   PubMed Web of Science ®Google Scholar
• Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87:206–10.
   PubMed Web of Science ®Google Scholar
• Spigset O, Mjörndal T. Serotonin 5-HT2A receptor binding in platelets from healthy subjects as studied by [3H]lysergic acid diethylamide ([3H]LSD): intra- and interindividual variability. Neuropsychopharmacol 1997;16:285–93.
   PubMedGoogle Scholar
• Neuger J, El Khoury A, Kjellman BF, et al. Platelet serotonin functions in untreated major depression. Psychiatry Res 1999;85:189–98.
   PubMed Web of Science ®Google Scholar
• Bixo M, Allard P, Bäckström T, et al. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to serotonin 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinol 2001;26: 551–64.
   PubMed Web of Science ®Google Scholar
• Smedh K, Spigset O, Allard P, et al. Platelet [3H]paroxetine and [3H]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapy. Biol Psychiatry 1999;45:464–70.
   PubMed Web of Science ®Google Scholar
• Alvarez JC, Gluck N, Arnulf I, et al. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin Pharmacol Ther 1999;66:617–24.
   PubMedGoogle Scholar
• Marazziti D, Dell'Osso L, Presta S, et al. Platelet [3H]paroxetine binding in patients with OCD-related disorders. Psychiatry Res 1999;89:223–28.
   PubMed Web of Science ®Google Scholar
• Delorme R, Betancur C, Callebert J, et al. Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder. Neuropsychopharmacol 2005;30:1539–47.
   PubMedGoogle Scholar
• Marazziti D, Rossi A, Dell'Osso L, et al. Decreased platelet 3H-paroxetine binding in untreated panic disorder patients. Life Sci. 1999;65:2735–41.
   PubMedGoogle Scholar
• Faludi G, Tekes K, Tóthfalusi L. Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls. J Psychiatry Neurosci 1994;19:109–13.
   PubMedGoogle Scholar
• Bazzichi L, Giannaccini G, Betti L, et al. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther 2006;8:R99.
   PubMed Web of Science ®Google Scholar
• Nankai M, Yamada S, Yoshimoto S, et al. Platelet 3H-paroxetine binding in control subjects and depressed patients: relationship to serotonin uptake and age. Psychiatry Res 1994;51:147–55.
   PubMedGoogle Scholar
• Maguire K, Norman T, Burrows G, et al. Platelet paroxetine binding in post-traumatic stress disorder. Psychiatry Res 1998;77:1–7.
   PubMedGoogle Scholar
• Mendelson SD. The current status of the platelet 5-HT2A receptor in depression. J Affect Disord 2000;57:13–24.
   PubMed Web of Science ®Google Scholar
• Pandey GN, Pandey SC, Ren X, Janciak PG. Serotonin receptors in platelets of bipolar and schizoaffective patients: effect of lithium treatment. Psychopharmacol 2003;170:115–23.
   Google Scholar
• Sigurdh J, Spigset O, Allard P, et al. Binding of [3H]lysergic acid diethylamide to serotonin 5-HT(2A) receptors and of [3H]paroxetine to serotonin uptake sites in platelets from healthy children, adolescents and adults. Neuropsychobiol 1999;40:183–7.
   PubMedGoogle Scholar
• Morris J, Twaddle S. Anorexia nervosa. BMJ 2007;334:894–8.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Fraser S, Stump K, et al. Dieting and weight loss in volunteers increases the number of α2-adrenoceptors and 5-HT receptors on blood platelets without effect on [3H]imipramine binding. J Affective Disord 1987;12:267–74.
   PubMedGoogle Scholar
• Rahm I, Spigset O, Mjörndal T. Dieting and weight loss do not affect the platelet 5-HT2A receptor. Eur Neuropsychopharmacol 2004;14:381–3.
   PubMedGoogle Scholar
• Iny LJ, Pecknold J, Suranyi-Cadotte BE, et al. Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry 1994;36:281–91.
   PubMed Web of Science ®Google Scholar
• Spigset O, Allard P, Mjörndal T. Circannual variations in binding of [3H]lysergic acid diethylamide to serotonin 5-HT2A receptors and of [3H]paroxetine to serotonin uptake sites in platelets from healthy volunteers. Biol Psychiatry 1998;43:774–80.
   PubMed Web of Science ®Google Scholar